No Data
No Data
Express News | HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target
Promising Clinical Data and Strategic Expansion Justify Buy Rating for Coherus Biosciences
Coherus BioSciences Reports Promising Clinical Data for CHS-114 Combined With Toripalimab in HNSCC and Gastric Cancer
Coherus Biosciences: Data From Ongoing Phase 1 Clinical Trial Evaluating CHS-114 Shows Clinical Efficacy And Proof Of Mechanism In HNSCC In Combination With Toripalimab
Coherus Presents Promising Early Clinical Data From Phase 1 Dose Expansion Study of CHS-114 in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
Coherus BioSciences Price Target Cut to $1.05/Share From $1.50 by UBS